drugset / Trial / NCT06897917

Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain

NCT06897917

Phase 4 Not yet recruiting 203 enrolled Henan Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study is a prospective, single-arm, multicenter, real-world study to evaluate effect of bowel function, analgesic effect, quality of life, and safety of Mimeixin® in Chinese patients with severe cancer pain.

Timeline

Start
2025-04
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Naloxone Small molecule 2.5 mg
Subject Naloxone Small molecule 5 mg
Subject Oxycodone Other / unclassified 5 mg
Subject Oxycodone Other / unclassified 10 mg